BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 34515355)

  • 1. Patient-reported outcomes and quality of life in dominant dystrophic epidermolysis bullosa: A global cross-sectional survey.
    Fulchand S; Harris N; Li S; Barriga M; Gorell E; De Souza M; Murrell D; Marinkovich MP; Krishna Yenamandra V; Tang JY
    Pediatr Dermatol; 2021 Sep; 38(5):1198-1201. PubMed ID: 34515355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient-reported outcomes and quality of life in recessive dystrophic epidermolysis bullosa: A global cross-sectional survey.
    Eng VA; Solis DC; Gorell ES; Choi S; Nazaroff J; Li S; de Souza MP; Murrell DF; Marinkovich MP; Tang JY
    J Am Acad Dermatol; 2021 Nov; 85(5):1161-1167. PubMed ID: 32199895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A global, cross-sectional survey of patient-reported outcomes, disease burden, and quality of life in epidermolysis bullosa simplex.
    So JY; Fulchand S; Wong CY; Li S; Nazaroff J; Gorell ES; de Souza MP; Murrell DF; Teng JM; Chiou AS; Tang JY
    Orphanet J Rare Dis; 2022 Jul; 17(1):270. PubMed ID: 35841105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ophthalmologic Approach in Epidermolysis Bullosa: A Cross-Sectional Study With Phenotype-Genotype Correlations.
    Mellado F; Fuentes I; Palisson F; I Vergara J; Kantor A
    Cornea; 2018 Apr; 37(4):442-447. PubMed ID: 29384803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Participatory co-design of patient-reported outcome indicators and N-of-1 evaluation of a dressing glove for Epidermolysis bullosa.
    Graham T; Sooriah S; Box R; Gage H; Williams P; Clemett V; Grocott P
    J Wound Care; 2020 Dec; 29(12):751-762. PubMed ID: 33320744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A systematic literature review of the disease burden in patients with recessive dystrophic epidermolysis bullosa.
    Tang JY; Marinkovich MP; Lucas E; Gorell E; Chiou A; Lu Y; Gillon J; Patel D; Rudin D
    Orphanet J Rare Dis; 2021 Apr; 16(1):175. PubMed ID: 33849616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hindi translation and validation of quality of life score in Indian patients with epidermolysis bullosa; and its correlation with the clinical severity assessment scores: A cross-sectional study.
    Bishnoi A; Manjunath S; Kishore K; De D; Handa S; Murrell DF; Mahajan R
    Indian J Dermatol Venereol Leprol; 2022; 88(2):177-183. PubMed ID: 34491666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical spectrum of dystrophic epidermolysis bullosa.
    Horn HM; Tidman MJ
    Br J Dermatol; 2002 Feb; 146(2):267-74. PubMed ID: 11903238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. QR-313, an Antisense Oligonucleotide, Shows Therapeutic Efficacy for Treatment of Dominant and Recessive Dystrophic Epidermolysis Bullosa: A Preclinical Study.
    Bornert O; Hogervorst M; Nauroy P; Bischof J; Swildens J; Athanasiou I; Tufa SF; Keene DR; Kiritsi D; Hainzl S; Murauer EM; Marinkovich MP; Platenburg G; Hausser I; Wally V; Ritsema T; Koller U; Haisma EM; Nyström A
    J Invest Dermatol; 2021 Apr; 141(4):883-893.e6. PubMed ID: 32946877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective short-term study to evaluate methodologies for the assessment of disease extent, impact, and wound evolution in patients with dystrophic epidermolysis bullosa.
    Paller AS; Pope E; Rudin D; Malyala A; Ramsdell D; Johnson R; Landy H; Murrell DF;
    Orphanet J Rare Dis; 2022 Aug; 17(1):314. PubMed ID: 35964087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Compound Heterozygosity of Dominant and Recessive COL7A Alleles in a Severely Affected Patient with a Family History of Dystrophic Epidermolysis Bullosa: Clinical Findings, Genetic Testing, and Treatment Implications.
    Watson KD; Schoch JJ; Beek GJ; Hand JL
    Pediatr Dermatol; 2017 Mar; 34(2):166-171. PubMed ID: 28297147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of the Timing of Milestone Clinical Events in Patients With Epidermolysis Bullosa From North America.
    Feinstein JA; Jambal P; Peoples K; Lucky AW; Khuu P; Tang JY; Lara-Corrales I; Pope E; Wiss K; Hook KP; Levin LE; Morel KD; Paller AS; McCuaig CC; Powell J; Eichenfield LF; Price H; Levy ML; Schachner LA; Browning JC; Bayliss S; Jahnke M; Shwayder T; Glick SA; Bruckner AL
    JAMA Dermatol; 2019 Feb; 155(2):196-203. PubMed ID: 30586139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved erythema and decreased blister formation in dominant dystrophic epidermolysis bullosa following treatment with pulsed dye laser.
    Garza-Mayers AC; Su KA; Wiss K
    Pediatr Dermatol; 2022 Nov; 39(6):1005-1006. PubMed ID: 36063122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermolysis Bullosa (EB) Acquisita in an Adult Patient with Previously Unrecognized Mild Dystrophic EB and Biallelic COL7A1 Mutations.
    Guerra L; Condorelli AG; Fortugno P; Calabresi V; Pedicelli C; Di Zenzo G; Castiglia D
    Acta Derm Venereol; 2018 Apr; 98(4):411-415. PubMed ID: 29182795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidermolysis Bullosa: Pediatric Perspectives.
    Hon KL; Chu S; Leung AKC
    Curr Pediatr Rev; 2022; 18(3):182-190. PubMed ID: 34036913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of mobility, activities and pain in different subtypes of epidermolysis bullosa.
    Fine JD; Johnson LB; Weiner M; Suchindran C
    Clin Exp Dermatol; 2004 Mar; 29(2):122-7. PubMed ID: 14987264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inside out: regenerative medicine for recessive dystrophic epidermolysis bullosa.
    Vanden Oever M; Twaroski K; Osborn MJ; Wagner JE; Tolar J
    Pediatr Res; 2018 Jan; 83(1-2):318-324. PubMed ID: 29593249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A rare case of recessive dystrophic epidermolysis bullosa with aplasia cutis and pyloric stenosis.
    Sawka E; Dhossche J; Funk T
    JAAD Case Rep; 2021 Jan; 7():134-136. PubMed ID: 33426253
    [No Abstract]   [Full Text] [Related]  

  • 19. Rat model for dominant dystrophic epidermolysis bullosa: glycine substitution reduces collagen VII stability and shows gene-dosage effect.
    Nyström A; Buttgereit J; Bader M; Shmidt T; Ozcelik C; Hausser I; Bruckner-Tuderman L; Kern JS
    PLoS One; 2013; 8(5):e64243. PubMed ID: 23717576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exon 87 skipping of the COL7A1 gene in dominant dystrophic epidermolysis bullosa.
    Koga H; Hamada T; Ishii N; Fukuda S; Sakaguchi S; Nakano H; Tamai K; Sawamura D; Hashimoto T
    J Dermatol; 2011 May; 38(5):489-92. PubMed ID: 21352278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.